clindamycin

Disclaimer to the Online Edition

This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.

clindamycin

Indication

  • Treatment of infections caused by anaerobic bacteria and some gram-positive cocci

Dosage Guidelines

Postnatal Age

Weight (kg)

Dose

All

Less than 1.2

5 mg/kg/dose IV q12h

0 to 7 days

1.2 to 2

5 mg/kg/dose IV q12h

Greater than 2

5 mg/kg/dose IV q8h

Greater than 7 days

1.2 to 2

5 mg/kg/dose IV q8h

Greater than 2 kg

5–7.5 mg/kg/dose IV q6h

Administration

  • IV intermittent slow infusion over 30 minutes
  • To make 10 mL of a 12 mg/mL solution:
  1. Draw up 0.8 mL of the 150 mg/mL solution
  2. Add to 9.2 mL D5W to make a total volume of 10 mL

Adverse Effects

  • Diarrhea, colitis, rash
  • Neutropenia, thrombocytopenia
  • Increased liver function tests (transient)
  • Hypotension and cardiopulmonary arrest with rapid IV administration

Comments

  • Poor CNS penetration, not to be used in meningitis

Supplied As

  • 150 mg/mL vial
  • 12 mg/mL patient specific syringe, prepared by Pharmacy